Physician profile
Roy Guinto
NPI 1427378884
$3,017.88
in general payments reported to CMS, 2019-2025
10 companies · $581 in 2025
The $581 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $12.72 · 2021: $108 · 2022: $651 · 2023: $1,100 · 2024: $341 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $827.61 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Tandem Diabetes Care, INC. | $470.68 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $459.96 | 2022-2025 | Evenity |
| Sanofi-Aventis U.S. LLC | $298.53 | 2023-2025 | |
| Novo Nordisk INC | $266.32 | 2022 | |
| Corcept Therapeutics | $224.71 | 2019 | |
| Abbott Laboratories | $137.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.30 | 2023 | |
| Lilly USA, LLC | $114.30 | 2023 | Mounjaro |
| Horizon Therapeutics Plc | $103.60 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Guinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.